Insights
Search Results
Client Highlights
7.27.26
Firm Advises Forte Biosciences on $2.2 Billion Acquisition by argenx
On July 27, 2026, argenx, a global immunology innovation company, and Forte Biosciences, a clinical-stage biopharmaceutical company, announced that they have entered into a definitive agreement under which argenx will acquire Forte Biosciences for $77.00 per share in cash, representing a total equity value of approximately $2.2 billion. FB102, Forte Biosciences’ lead program, expands argenx’s portfolio of differentiated immunology medicines, adding a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease and potential to address multiple autoimmune diseases. Wilson Sonsini Goodrich & Rosati advised Forte Biosciences on the transaction.
Client Highlights
7.08.26
Wilson Sonsini Advises Crinetics on Patent Matters Related to $10 Billion Acquisition by Vertex
On July 6, 2026, Vertex Pharmaceuticals and Crinetics Pharmaceuticals, a global pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases, announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10 billion, or approximately $8.8 billion net of estimated cash acquired. Wilson Sonsini Goodrich & Rosati is patent counsel to Crinetics and advised the company on patent matters related to the transaction.
Podcasts
7.07.26
NextGen VC Podcast – Why the Future of Biotech Starts with the Brain
What does neuroscience have to do with venture capital? Quite a bit, according to Jason Pitts, Ph.D., principal at General Atlantic. In the latest episode of the NextGen VC Podcast, hosts and Wilson Sonsini partners Mike Hostetler and Jen Fang sit down with Jason to talk about the winding path that took him from studying the brain at Cornell University to evaluating some of the most promising companies in biotech.
Client Highlights
6.24.26
Firm Advises Underwriters on Legend Biotech’s Public Offering
On June 17, 2026, Legend Biotech Corporation, a global leader in cell therapy, announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (ADSs), each representing two ordinary shares of the company, at a public offering price of $29.35 per ADS. In addition, Legend Biotech has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 ADSs at the public offering price, less underwriting discounts and commissions. The gross proceeds to Legend Biotech from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Legend Biotech, were approximately $226 million, excluding any proceeds from the exercise of the underwriters’ option to purchase additional ADSs. Wilson Sonsini Goodrich & Rosati advised the underwriters on the transaction.
Podcasts
6.08.26
NextGen VC Podcast – The $2.25 Billion Exit That Changed Lumira’s Investment Strategy: Suman Rao of Lumira Ventures
In the latest episode of the NextGen VC Podcast, Suman Rao, Ph.D., principal at Lumira Ventures, joins hosts and Wilson Sonsini partners Michael Hostetler and Jennifer Fang to discuss her path from academic science to healthcare venture capital and why she believes the best investors lead with mission before money.
News Articles
6.04.26
Wilson Sonsini Practices, Attorneys Recognized in 2026 Chambers USA Guide
The 2026 Chambers USA guide has recognized Wilson Sonsini Goodrich & Rosati as a leading law firm in 44 geography-specific practice categories and named 87 Wilson Sonsini attorneys among the best in their fields. This year, the firm received four new practice area rankings, including in the nationwide National Security and Capital Markets: Convertible Debt categories, and three improved practice area rankings.
Client Highlights
6.02.26
Wilson Sonsini Advises BVF Partners on IP Matters Related to Contraline’s $92.5 Million Series B
On June 2, 2026, Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. Wilson Sonsini Goodrich & Rosati advised BVF Partners on IP matters related to the transaction.
News Articles
5.21.26
Michael Hostetler Recognized Among Daily Journal’s 2026 Top IP Lawyers
On May 21, 2026, Wilson Sonsini partner Michael Hostetler was recognized in the Daily Journal’s special report "Top Intellectual Property Lawyers 2026," an annual list honoring California's top lawyers specializing in patent litigation, trademark, and copyright. Michael has over 25 years of experience specializing in patent law for life sciences companies, particularly in pharmaceuticals and biotechnology.
Client Highlights
5.11.26
Wilson Sonsini Advises Odyssey Therapeutics on Patent Matters Related to IPO
On May 7, 2026, Odyssey Therapeutics, a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, announced the pricing of its upsized initial public offering of 15,500,000 shares of its common stock at an initial public offering price of $18.00 per share. In addition, Odyssey has granted the underwriters a 30-day option to purchase up to an additional 2,325,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Odyssey’s common stock began trading on the Nasdaq Capital Market on May 8, 2026, under the ticker symbol “ODTX.” The offering closed on May 11, 2026. Wilson Sonsini Goodrich & Rosati advised Odyssey on patent matters related to the transaction.
Podcasts
5.07.26
NextGen VC Podcast - Building Biotech Companies from Day One: Aimee Raleigh of Atlas Venture
What does it actually take to turn an idea into a biotech company? In the latest episode of the NextGen VC Podcast, Aimee Raleigh, Ph.D., principal at Atlas Venture, joins hosts and Wilson Sonsini partners Michael Hostetler and Jennifer Fang to explore how companies get built before they’re even companies.
From evaluating early science to forming a real point of view, Aimee shares how investors build conviction at the earliest stages. She discusses the pace of early-stage venture, as well as how to juggle multiple opportunities, make decisions with imperfect data, and figure out what’s worth leaning into, among other topics. Aimee also discusses her path into venture and what she’s learned along the way in an industry that doesn’t slow down.
From evaluating early science to forming a real point of view, Aimee shares how investors build conviction at the earliest stages. She discusses the pace of early-stage venture, as well as how to juggle multiple opportunities, make decisions with imperfect data, and figure out what’s worth leaning into, among other topics. Aimee also discusses her path into venture and what she’s learned along the way in an industry that doesn’t slow down.
Client Highlights
5.04.26
Firm Advises Candid Therapeutics on Patent Matters Related to Its $2 Billion Acquisition by UCB
On May 3, 2026, UCB, a global biopharmaceutical company, announced a definitive agreement to acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers. Under the terms of the agreement, UCB will pay $2 billion in upfront payments and up to $200 million in potential future milestone payments. Wilson Sonsini Goodrich & Rosati advised Candid on patent matters related to the transaction.
Podcasts
4.09.26
NextGen VC Podcast – From Scalpel to Term Sheet: Rich Gaster of venBio
In the latest episode of the NextGen VC Podcast, Rich Gaster, M.D., Ph.D., managing partner at venBio, joins hosts and Wilson Sonsini partners Michael Hostetler and Jennifer Fang to discuss what it takes to go from performing reconstructive plastic surgeries at Harvard to becoming a managing partner at one of biotech’s most focused venture firms. He traces a career path that runs through Stanford M.D.-Ph.D. training, two grad school start-ups, the company-building engine at Third Rock Ventures, and the founding team of Pliant Therapeutics before landing at venBio, where he helped engineer three back-to-back acquisitions in a single quarter.